Phase I
Moderna is expected to launch a human clinical trial as early as this week for an mRNA-based vaccine against HIV and indicated that it is looking for 56 people ages 18 to 50 who are HIV-negative.
Patient enrollment in the Phase I study will resume, the company announced this morning.
There was plenty of clinical trial updates last week. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
It was a busy week for clinical trial announcements. Take a look.
With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space.
The drug, created by Vaxart, has just completed its Phase I trial and had submitted an Investigational New Drug application to move forward.
With the Alzheimer’s Association International Conference conference last week, there were plenty of clinical trial news and updates. Here’s a look.
Clinical-stage biotech company Vaxart announced Thursday that a second dose of its oral norovirus vaccine boosted immunity in clinical trial participants who had previously received the vaccine more than a year prior.
The company’s pipeline was strengthened in the second quarter with three strategic collaborations in immuno-oncology, immuno-neurology, and HIV.
PRESS RELEASES